Advertisement Pharmaceutical Business review - Page 295 of 5255 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 6, 2026

Arrowhead receives Health Canada authorisation for Redemplo to treat FCS

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, Redemplo (plozasiran), as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) who have not responded to standard therapies.

The therapy can be self-administered at home via subcutaneous injection every three months. Credit: Davidzro Photography / Shutterstock.com.